These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 36791639)

  • 1. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature.
    Boutros A; Bottini A; Rossi G; Tanda ET; Spagnolo F; Barletta G; Croce E; Fava P; Parisi A; De Rosa F; Palla M; Marconcini R; Ferrari M; Grandis M; Spallarossa P; Sarocchi M; Arboscello E; Del Mastro L; Lambertini M; Pronzato P; Genova C
    ESMO Open; 2023 Feb; 8(1):100791. PubMed ID: 36791639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer].
    Ying YC; Tang Q; Yang KW; Mi Y; Fan Y; Yu W; Song Y; He ZS; Zhou LQ; Li XS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):644-651. PubMed ID: 35950386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea.
    Hyun JW; Kim KH; Kim SH; Kim HJ
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):5583-5589. PubMed ID: 36495331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases.
    Pathak R; Katel A; Massarelli E; Villaflor VM; Sun V; Salgia R
    Oncologist; 2021 Dec; 26(12):1052-1061. PubMed ID: 34378270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis.
    Hamada N; Maeda A; Takase-Minegishi K; Kirino Y; Sugiyama Y; Namkoong H; Horita N; Yoshimi R; Nakajima H;
    Front Immunol; 2021; 12():803410. PubMed ID: 34938300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Inhibition-Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade.
    Nelke C; Pawlitzki M; Kerkhoff R; Schroeter CB; Aktas O; Neuen-Jacob E; Polzin A; Meuth SG; Ruck T
    Neurol Neuroimmunol Neuroinflamm; 2024 Jan; 11(1):. PubMed ID: 37884388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit.
    Deharo F; Carvelli J; Cautela J; Garcia M; Sarles C; Maues de Paula A; Bourenne J; Gainnier M; Bichon A
    J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case Report: Glucocorticoid Effect Observation in a Ureteral Urothelial Cancer Patient With ICI-Associated Myocarditis and Multiple Organ Injuries.
    Hu X; Wei Y; Shuai X
    Front Immunol; 2021; 12():799077. PubMed ID: 34975911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series.
    Vicino A; Hottinger AF; Latifyan S; Boughdad S; Becce F; Prior JO; Kuntzer T; Brouland JP; Dunet V; Obeid M; Théaudin M
    J Neurol; 2024 Apr; 271(4):1947-1958. PubMed ID: 38141128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program.
    Naqash AR; Moey MYY; Cherie Tan XW; Laharwal M; Hill V; Moka N; Finnigan S; Murray J; Johnson DB; Moslehi JJ; Sharon E
    J Clin Oncol; 2022 Oct; 40(29):3439-3452. PubMed ID: 35658474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral nervous system adverse events associated with immune checkpoint inhibitors.
    Rossi S; Gelsomino F; Rinaldi R; Muccioli L; Comito F; Di Federico A; De Giglio A; Lamberti G; Andrini E; Mollica V; D'Angelo R; Baccari F; Zenesini C; Madia P; Raschi E; Cortelli P; Ardizzoni A; Guarino M
    J Neurol; 2023 Jun; 270(6):2975-2986. PubMed ID: 36800019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
    Reynolds KL; Guidon AC
    Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CNS and PNS manifestation in immune checkpoint inhibitors: A systematic review.
    Khan E; Shrestha AK; Elkhooly M; Wilson H; Ebbert M; Srivastava S; Wen S; Rollins S; Sriwastava S
    J Neurol Sci; 2022 Jan; 432():120089. PubMed ID: 34942546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
    Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians.
    Raschi E; Rossi S; De Giglio A; Fusaroli M; Burgazzi F; Rinaldi R; Potena L
    Drug Saf; 2023 Sep; 46(9):819-833. PubMed ID: 37341925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors.
    Jordan B; Benesova K; Hassel JC; Wick W; Jordan K
    ESMO Open; 2021 Dec; 6(6):100317. PubMed ID: 34839103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case report and literature review on respiratory failure with immune checkpoint inhibitors: a life-threatening adverse event.
    Lin X; Guan W; Li B; Deng H; Chen Y; Yang Y; Qiu G; Xie X; Zhou C
    Immunopharmacol Immunotoxicol; 2023 Dec; 45(6):780-787. PubMed ID: 37339370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome.
    Lipe DN; Galvis-Carvajal E; Rajha E; Wechsler AH; Gaeta S
    Am J Emerg Med; 2021 Aug; 46():51-55. PubMed ID: 33721590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Aldrich J; Pundole X; Tummala S; Palaskas N; Andersen CR; Shoukier M; Abdel-Wahab N; Deswal A; Suarez-Almazor ME
    Arthritis Rheumatol; 2021 May; 73(5):866-874. PubMed ID: 33258544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab-Induced Fatal Myasthenia, Myocarditis, and Myositis in a Patient with Metastatic Melanoma: Autopsy, Histological, and Immunohistochemical Findings-A Case Report and Literature Review.
    Giovannini E; Bonasoni MP; D'Aleo M; Tamagnini I; Tudini M; Fais P; Pelotti S
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.